Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Review Article

Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia

Author(s): Alessandro Gozzetti*, Veronica Candi, Corrado Zuanelli Brambilla, Giulia Papini, Alberto Fabbri and Monica Bocchia

Volume 17, Issue 8, 2017

Page: [1040 - 1045] Pages: 6

DOI: 10.2174/1871520616666160928153342

Price: $65

Abstract

Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton’s tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.

Keywords: CLL, chemotherapy, BTK, BCR, tyrosine, kinase.

Graphical Abstract


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy